Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 22 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

456 External validation of the SITC consensus definitions of primary and secondary resistance to immune checkpoint inhibitors in patients with solid tumors

  • Ali Awada1
  • Sary Faraj2
  • Ali Tarhini3
  • Firas Kreidieh4
  • Nicole Charbel2
  • Mohammad Kassem2
  • Teia El Hajj2
  • Mahdi Mansour2
  • Akel Khaled2
  • Rani Hassan2
  • Ali Hajj Ali2
  • Lara Soueid2
4 more authors
  • Duha Awada5
  • Mohammad Hassan2
  • Ahmad Moukachar2
  • Heba Sati2
5 affiliations
  1. 1Beirut, Lebanon
  2. 2American University of Beirut Medical Center, Beirut, Lebanon
  3. 33University of Balamand, Beirut, Lebanon
  4. 42American University of Beirut Medical Center, Beirut, Lebanon
  5. 5University of Balamand, Beirut, Lebanon
Open at sourcePDFDOICite

Related

  1. Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
    Martina Milella, Francesco Lasorsa, Monica Rutigliano +5
    CellsPeer-reviewedCC BY 4.0OncologyCrossref
  2. Mechanisms of resistance to immune checkpoint inhibitors in renal cell carcinoma and novel treatment strategies
    Li Chen, Jie Cheng, Shilong Mao
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  3. Mechanisms of Resistance and Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Narrative Review.
    Jin Li, Jin-Yi Zhou, Yue Yu +11
    Journal of hepatocellular carcinomaPeer-reviewedCC BY-NCFull textOncologyEurope PMCPMC
  4. Fibrinogen alpha chain is associated with response to immune checkpoint inhibitors in non-small cell lung cancer: a multi-cohort discovery and validation study.
    Hongge Liang, Yan Xu, Minjiang Chen +3
    Journal of translational medicinePeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  5. Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
    Alessandro Russo, Christian Rolfo, Mariacarmela Santarpia
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref

Cite

BibTeXRIS
BibTeX
@article{awada2026external,
  title = {{456 External validation of the SITC consensus definitions of primary and secondary resistance to immune checkpoint inhibitors in patients with solid tumors}},
  author = {Ali Awada and Sary Faraj and Ali Tarhini and Firas Kreidieh and Nicole Charbel and Mohammad Kassem and Teia El Hajj and Mahdi Mansour and Akel Khaled and Rani Hassan and Ali Hajj Ali and Lara Soueid and Duha Awada and Mohammad Hassan and Ahmad Moukachar and Heba Sati},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0456},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0456},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 456 External validation of the SITC consensus definitions of primary and secondary resistance to immune checkpoint inhibitors in patients with solid tumors
AU  - Ali Awada
AU  - Sary Faraj
AU  - Ali Tarhini
AU  - Firas Kreidieh
AU  - Nicole Charbel
AU  - Mohammad Kassem
AU  - Teia El Hajj
AU  - Mahdi Mansour
AU  - Akel Khaled
AU  - Rani Hassan
AU  - Ali Hajj Ali
AU  - Lara Soueid
AU  - Duha Awada
AU  - Mohammad Hassan
AU  - Ahmad Moukachar
AU  - Heba Sati
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0456
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0456
SN  - 2051-1426
ER  -